Fortress Biotech, Inc.
FBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $58 | $85 | $76 | $69 |
| % Growth | -31.8% | 11.6% | 10.1% | – |
| Cost of Goods Sold | $21 | $23 | $31 | $32 |
| Gross Profit | $37 | $62 | $45 | $37 |
| % Margin | 63.8% | 72.9% | 59.4% | 53.4% |
| R&D Expenses | $57 | $106 | $135 | $129 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $88 | $91 | $114 | $87 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $7 | $0 | $10 |
| Operating Expenses | $147 | $204 | $249 | $225 |
| Operating Income | -$110 | -$142 | -$204 | -$189 |
| % Margin | -191.4% | -168.4% | -268.8% | -274.1% |
| Other Income/Exp. Net | -$10 | -$11 | -$10 | $24 |
| Pre-Tax Income | -$121 | -$154 | -$213 | -$164 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$46 | -$61 | -$87 | -$65 |
| % Margin | -79.8% | -71.7% | -114.3% | -94.1% |
| EPS | -2.69 | -8.47 | -14.55 | -11.85 |
| % Growth | 68.2% | 41.8% | -22.8% | – |
| EPS Diluted | -2.69 | -8.47 | -14.55 | -11.85 |
| Weighted Avg Shares Out | 21 | 8 | 6 | 5 |
| Weighted Avg Shares Out Dil | 21 | 8 | 6 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $1 | $1 |
| Interest Expense | $10 | $13 | $14 | $15 |
| Depreciation & Amortization | $4 | $6 | $9 | $7 |
| EBITDA | -$104 | -$136 | -$194 | -$146 |
| % Margin | -181.2% | -160.6% | -255.7% | -212.5% |